International Collaborative Study Reveals The Neuroprotective Properties of Phytocannabinoid Δ9-THCA

A recent Δ9-THCA (Δ9-tetrahydrocannabinol acid) study, initiated by three leading companies active in the field of medicinal cannabis research, has demonstrated its ability as a promising treatment modality for Huntington's disease (HD) and other metabolic, neurodegenerative and neuroinflammatory diseases.

SPAIN:  Advanced medical research conducted at Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC) as a collaborative effort between Phytoplant Research SL, VivaCell Biotechnology España SL, and Emerald Health Pharmaceuticals has unveiled the potent neuroprotective ability of Δ9-THCA, a phytocannabinoid produced in Cannabis sativa L. The research paper was accepted and published in the British Journal of Pharmacology. Read the full article…